Continued Chinese dumping in salicylic acid
Chinese dumping persists, pressuring realizations. Management plans to file anti-dumping application by April 2026, but relief may take 6-8 months.
high · management_commentaryAarti Drugs Limited — Q3 FY26
Aarti Drugs reported a mixed Q3 FY26 with consolidated revenue of ₹602.9 crore (+8% YoY) but EBITDA margin contracting to 9.3% (-180bps YoY) due to low capacity utilization, Chi...
neutral
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Slow ramp-up of greenfield facilities
Salicylic acid plant ramp-up slower than expected due to technology changes and quality parameter adjustments, delaying profitability.
medium · management_commentaryAntibiotic demand weakness
Weaker antibiotic demand reduced overall market pool, leading to lower capacity utilization and margin pressure. Management noted this as a key headwind.
medium · management_commentaryHigh capex despite recent investments
Analyst raised concern about continued high capex (₹150-200 Cr/year) while new plants are still scaling up. Management defended citing smooth Sikar ramp-up and need for oncology investment.
medium · analyst_question